Search research articles
Contact Us
Filters
Showing results (81-90 of 175) with videos related to
Page
of 18
Sort By:
Nederlands Tijdschrift Voor Geneeskunde
|
December 2, 2010
[Long-term complications following treatment of testicular cancer and Hodgkin lymphoma]
A W Sandra van den Belt-Dusebout, Berthe M P Aleman, Jourik A Gietema, et al.
Molecular Oncology
|
February 7, 2017
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions
Lisanne F van Dessel, Nick Beije, Jean C A Helmijr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer
Alexandra W van den Belt-Dusebout, Ronald de Wit, Jourik A Gietema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
<sup>68</sup>Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer
Anouk C de Jong, Minke Smits, Job van Riet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2014
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities
Marieke van Leeuwen, Fabio Efficace, Sophie D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
Glenn Heller, Robert McCormack, Thian Kheoh, et al.
European Urology
|
April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
British Journal of Cancer
|
August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancer
Ellen S de Morrée, René Böttcher, Robert J van Soest, et al.
JCI Insight
|
November 4, 2025
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
Ossian Longoria, Jan Rekowski, Santosh Gupta, et al.
European Urology Oncology
|
May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Petros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Page
of 18
Search research articles
Search
Showing results (81-90 of 175) with videos related to
Sort By:
Page
of 18
Nederlands Tijdschrift Voor Geneeskunde
|
December 2, 2010
[Long-term complications following treatment of testicular cancer and Hodgkin lymphoma]
A W Sandra van den Belt-Dusebout, Berthe M P Aleman, Jourik A Gietema, et al.
Molecular Oncology
|
February 7, 2017
Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions
Lisanne F van Dessel, Nick Beije, Jean C A Helmijr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 2, 2007
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer
Alexandra W van den Belt-Dusebout, Ronald de Wit, Jourik A Gietema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 15, 2020
<sup>68</sup>Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer
Anouk C de Jong, Minke Smits, Job van Riet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 14, 2014
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities
Marieke van Leeuwen, Fabio Efficace, Sophie D Fosså, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 23, 2017
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
Glenn Heller, Robert McCormack, Thian Kheoh, et al.
European Urology
|
April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
British Journal of Cancer
|
August 19, 2016
Loss of SLCO1B3 drives taxane resistance in prostate cancer
Ellen S de Morrée, René Böttcher, Robert J van Soest, et al.
JCI Insight
|
November 4, 2025
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer
Ossian Longoria, Jan Rekowski, Santosh Gupta, et al.
European Urology Oncology
|
May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Petros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Page
of 18